Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1985 5
1987 3
1988 7
1989 8
1990 12
1991 11
1992 15
1993 15
1994 21
1995 16
1996 12
1997 20
1998 15
1999 21
2000 26
2001 35
2002 44
2003 78
2004 73
2005 82
2006 121
2007 108
2008 124
2009 174
2010 174
2011 185
2012 279
2013 347
2014 378
2015 506
2016 562
2017 542
2018 618
2019 673
2020 754
2021 871
2022 1036
2023 1074
2024 248

Text availability

Article attribute

Article type

Publication date

Search Results

8,326 results

Results by year

Filters applied: . Clear all
Page 1
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Among authors: ren h. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
A tool kit of highly selective and sensitive genetically encoded neuropeptide sensors.
Wang H, Qian T, Zhao Y, Zhuo Y, Wu C, Osakada T, Chen P, Chen Z, Ren H, Yan Y, Geng L, Fu S, Mei L, Li G, Wu L, Jiang Y, Qian W, Zhang L, Peng W, Xu M, Hu J, Jiang M, Chen L, Tang C, Zhu Y, Lin D, Zhou JN, Li Y. Wang H, et al. Among authors: ren h. Science. 2023 Nov 17;382(6672):eabq8173. doi: 10.1126/science.abq8173. Epub 2023 Nov 17. Science. 2023. PMID: 37972184
Metabolic biomarkers significantly enhance the prediction of HBV-related ACLF occurrence and outcomes.
Zhang Y, Tan W, Wang X, Zheng X, Huang Y, Li B, Meng Z, Gao Y, Qian Z, Liu F, Lu X, Shi Y, Shang J, Yan H, Zheng Y, Zhang W, Gu W, Qiao L, Deng G, Zhou Y, Hou Y, Zhang Q, Xiong S, Liu J, Duan L, Chen R, Chen J, Jiang X, Luo S, Chen Y, Jiang C, Zhao J, Ji L, Mei X, Li J, Li T, Zheng R, Zhou X, Ren H, Cheng X, Guo L, Li H; Chinese (Acute on) Chronic Liver Failure Consortium (Ch-CLIF.C). Zhang Y, et al. Among authors: ren h. J Hepatol. 2023 Nov;79(5):1159-1171. doi: 10.1016/j.jhep.2023.07.011. Epub 2023 Jul 29. J Hepatol. 2023. PMID: 37517452
Metabolic reprogramming in skin wound healing.
Wang Z, Zhao F, Xu C, Zhang Q, Ren H, Huang X, He C, Ma J, Wang Z. Wang Z, et al. Among authors: ren h. Burns Trauma. 2024 Jan 2;12:tkad047. doi: 10.1093/burnst/tkad047. eCollection 2024. Burns Trauma. 2024. PMID: 38179472 Free PMC article. Review.
Lactylation constrains OXPHOS under hypoxia.
Ren H, Zhang D. Ren H, et al. Cell Res. 2024 Feb;34(2):91-92. doi: 10.1038/s41422-023-00872-6. Cell Res. 2024. PMID: 38163845 No abstract available.
Review of Predicting Synergistic Drug Combinations.
Pan Y, Ren H, Lan L, Li Y, Huang T. Pan Y, et al. Among authors: ren h. Life (Basel). 2023 Sep 7;13(9):1878. doi: 10.3390/life13091878. Life (Basel). 2023. PMID: 37763281 Free PMC article. Review.
8,326 results